A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To examine the continued safety and tolerability of four doses of vesnarinone in HIV-infected patients who have completed a short-term study (less than 12 months on continuous treatment) of the drug.
Condition or disease
Patients who have completed a limited duration study (less than 12 months of continuous treatment) of vesnarinone on protocols FDA 234A or FDA 234B and who have no current signs or symptoms of AIDS-defining illnesses may roll over to this study and continue receiving their regimen of vesnarinone for 12 months beyond their original participation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Chemoprophylaxis for Pneumocystis carinii, candida, and mycobacteria.
Acyclovir for acute treatment of herpes.
Antiretroviral agents, including ddI, ddC, AZT, and d4T.
Investigational HIV drugs/therapies including vaccines.
Interferon or other immunomodulating agents.
Corticosteroids (other than topical).
Agents known to cause neutropenia.
Patients with the following prior conditions are excluded:
Poor compliance (less than 80 percent of drug taken) on the Phase I protocol (FDA 234A or FDA 234B).
Missed more than one clinic visit on the Phase I protocol.
Acyclovir as prophylaxis for herpes within 48 hours prior to study entry.
Patients meet the following criteria:
Successful completion of short-term therapy with vesnarinone on FDA 234A or FDA 234B.